TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02833350

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
Study: NCT00093795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 IV every 21 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 2000 mg/m2 IV every 14 days for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2 IV every 14 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 IV every 14 days for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles
Study: NCT01195675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 (low)
Description: single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 10773 Placebo
Description: 2 times single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 (high)
Description: single oral dose
Study: NCT04040543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lipid-based nutrient supplement containing adherence markers
Description: The supplement will be provided once daily for 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lipid-based nutrient supplement containing or not containing adherence markers
Description: The product containing adherence markers will be provided once daily every other day (5 days total); the product not containing adherence markers will be provided on the intervening days for a total of 10 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lipid-based nutrient supplement not containing adherence markers
Description: The supplement will be provided once daily for 10 days
Study: NCT00606866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for four weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 200 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib, 400 mg twice daily
Study: NCT01953809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322
Description: Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322
Description: Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322
Description: Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/NE
Description: Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/NE
Description: Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/NE
Description: Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/NE
Description: Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 Placebo
Description: GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 Placebo
Description: GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 Placebo
Description: GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/NE Placebo
Description: EE/NE matching placebo tablet for once daily administration for 7 days in run-in phase.
Study: NCT01207908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-1
Description: IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
Study: NCT00161447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: Testosterone Gel (10 g daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: Testosterone Gel (10 g daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medroxyprogesterone
Description: DMPA (injected into muscle) Day 0 \& month 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medroxyprogesterone
Description: DMPA (injected into muscle) Day 0 \& month 3
Study: NCT04616365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Semi-Elective Lung Transplantation
Description: When suitable donor lungs become available for a consented recipient, the transplant procedure (anesthesia starting time) will be allowed to begin earliest at 6am with the lungs being preserved at 10°C cold static preservation upon organ arrival to our hospital using a specific incubator, regardless of when donor cross clamp occurs. The maximum time allowed between donor cross clamp and recipient anesthesia initiation will be 12h.
Study: NCT01306331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conceptrol
Description: • Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphora
Description: • Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
Study: NCT02836665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemedicine for dermatological emergency patients
Description: Study-related photographs of the skin lesion made by a tablet and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal without being on site.
Study: NCT04046523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video ophthalmoscope
Description: Use of a custom video ophthalmoscope with either a CCD or CMOS camera lens. The healthy controls group (first 20 subjects) will provide data to help determine which lens might be best for measuring ICP patients (Groups A and B) in the second phase of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video ophthalmoscope
Description: Use of a custom video ophthalmoscope with either a CCD or CMOS camera lens. The healthy controls group (first 20 subjects) will provide data to help determine which lens might be best for measuring ICP patients (Groups A and B) in the second phase of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video ophthalmoscope
Description: Use of a custom video ophthalmoscope with either a CCD or CMOS camera lens. The healthy controls group (first 20 subjects) will provide data to help determine which lens might be best for measuring ICP patients (Groups A and B) in the second phase of the study.
Study: NCT04257851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline Anhydrous Oral Tablet
Description: Theophylline tablet (150 mg/12h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan Succinate Oral Tablet
Description: Sumatriptan tablet (25 mg/12h)
Study: NCT03879967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allograft block graft
Description: The graft used is a mineralized, cortico-cancellous, delipidized, lyophilized allogenic block.
Study: NCT04167709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education in clinical competence in detecting signs of postpartum depression in immigrant mothers
Description: Groupbased educational intervention aimed at nurses in the Child Health Services in strengthening clinical competence in detecting signs of postpartum depression in non-native-speaking immigrant mothers
Study: NCT01766830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAT Serostrip
Description: The HAT Serostrip is an immunochromatographic assay developed by Coris BioConcept, France, which is designed for remote field use in individual HAT suspects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Card Agglutination Trypanosoma Test (CATT)-10
Description: The Card Agglutination Trypanosoma test (CATT) has been used for many years at large scale for mass screening of mostly asymptomatic individuals (CATT-R250). Unfortunately, its operating characteristics have only been evaluated in the context of patients with persistent fever. Although it is not strictly an RDT, the CATT is rather easily performed in remote settings, in particular since a new and more robust format (CATT-D10) allows to test a lower number of patients in peripheral health facilities. It is manufactured by the Institute of Tropical Medicine of Antwerp, Belgium.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Typhidot M
Description: The Typhidot M test is a dot enzyme immunoassay that detects IgM and IgG directed against Salmonella typhi. It is manufactured by Reszon Diagnostics International, Malaysia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S. typhi IgM/IgG
Description: The Salmonella typhi IgG/IgM Rapid Test is an immunochromatographic assay for the qualitative differential detection of IgG and IgM antibodies to Salmonella typhi in human serum, plasma or whole blood. It is manufactured by Standard Diagnostics (Korea)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test-it Typhoid IgM
Description: Test-it Typhoid IgM lateral flow assay is a one-step immunochromatographic assay which uses a lipopolysaccharide (LPS) antigen derived from salmonella typhi for the detection of specific IgM antibodies. It is manufactured by Life Assay, South Africa.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test-it Leptospirosis IgM
Description: The Test-it™ Leptospira lateral flow device detects IgM antibodies in humans against Leptospira in whole blood or serum. It is manufactured by Life Assay, South Africa

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leptospira IgG/IgM
Description: This test enables the differential detection of IgG and IgM antibodies to Leptospira interrogans. It is manufactured by Standard Diagnostics, Korea
Study: NCT03651193

Intervention type: DIAGNOSTIC_TEST
Intervention: Exon sequencing and Methylated sequencing
Description: Exon sequencing and Methylated sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: Exon sequencing and Methylated sequencing
Description: Exon sequencing and Methylated sequencing
Study: NCT04497662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPL-404
Description: humanized IgG4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPL-404
Description: humanized IgG4 monoclonal antibody

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Placebo
Study: NCT01554956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Plasminogen
Description: Eye Drops
Study: NCT03487380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal sample collection
Description: Fecal sample collection
Study: NCT03386162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: fulvestrant (500 mg intramuscular \[as two 5 mL injections\] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
Study: NCT00916487

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructosin
Description: Three capsules of Fructosin before one of the hydrogen breath tests.
Study: NCT05424588

Intervention type: DIAGNOSTIC_TEST
Intervention: clinical evaluation, bioelectrical impedance analysis (BIA), cardiopulmonary exercise testing (CPET) and venipuncture for blood samples collection
Description: Total body dual-energy X-ray absorptiometry (DEXA) was taken BN and AN to measure total (FM) and segmental fat (truncal FM), visceral adipose tissue (VAT) and lean mass (LM). Tetra-polar dual frequency BIA (InBody 120; Cerritos, USA) was used BPP, BN and AN to measure weight and to estimate FM, FFM, and MM. Impedance measurements were performed. CPET was carried out on a cycle ergometer with clip-on pedals. Blood samples were collected in the morning BPP, BN, AN. Biochemical parameters considered in this study were: ALT, AST, creatinine, 25-hydroxy vitamin D, total cholesterol, HDL, LDL, triglycerides concentrations. We isolated CPCs from heparinized blood, as previously reported (14). After the collection of peripheral blood mononuclear cells (PBMCs) by a gradient centrifugation. (15). Differentiating Human Skeletal muscle cells were cultured with or without pooled sera of participants at 5% final concentration. 146b and 34a miRNAs were extracted from PBMCs.
Study: NCT02001792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Position the patient during colonoscopy
Description: Position the patient either in a left lateral position during colonoscopy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: pulse oximeter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulse oximeter
Study: NCT03723473

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.
Study: NCT01831908

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lifestyle counseling
Description: People attending the community center will be provided with information on their health problems and will receive advise on how to improve blood pressure, glucose and cholesterol levels.
Study: NCT03487380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal sample collection
Description: Fecal sample collection

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Fecal sample collection
Description: Fecal sample collection
Study: NCT00170248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computer-based decision support for asthma management
Description: The asthma management decision support system uses data from the patient problem and medication list to provide patient-specific management recommendations based on Canadian Consensus guidelines for asthma management. Web-enabled technology for asthma education nurses is used to collect home-monitoring information from patients between visits and feedback to primary care physicians in accordance with options selected by the physician for each patient.
Study: NCT04300933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electroencephalogram-based neurofeedback
Description: In this project, SCD participants will receive electroencephalogram-based neurofeedback therapy, once a day, for 5 days. Then, the investigators will compare their memory changes between baseline and post-therapy visits.
Study: NCT00208104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
Study: NCT03234621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilator setting during one-lung ventilation
Description: providing various tidal volumes according to the groups with constant PEEP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilator setting during one-lung ventilation
Description: providing various tidal volumes according to the groups with constant PEEP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilator setting during one-lung ventilation
Description: providing various tidal volumes according to the groups with constant PEEP
Study: NCT02098902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Moms Intervention
Description: Reduction in child sugar-sweetened beverage consumption and maternal caloric beverage consumption, in addition to self-selected 100-calorie dietary and physical activity changes made by the mother to promote modest weight loss. Content will be delivered via one in-person group meeting, weekly online lessons, and weekly text messages. Mothers will self-monitor their weight and their own and their child's beverage consumption via text message every 2-3 days.
Study: NCT03810482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: A pedometer will be worn by the patient at home for days 1 to 14 and 60 to 74.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 minute walking test
Description: Performed according to current recommendations during routine visits (baseline and \~90 days for the purposes of this study).
Study: NCT02711982

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Optic canal and optic nerve sheath decompression
Description: within 5 days from trauma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: within 5 days from trauma
Study: NCT01483287

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Galactosidase
Description: The study is conducted during a total of two days at two different occasions. Visit 1: The patients will be served breakfast and lunch at the gastro unit and dinner will be enclosed when the patient leave for home. At each meal (breakfast, lunch, and dinner) the participants will ingest three capsules with a total content of 1200 GaIU alpha-galactosidase-randomized to be either the enzyme (α-Galactosidase) or a non-active substance (placebo). Visit 2: The procedure from visit 1 will recur after at least two weeks has passed - except that the content of the capsules will be opposite from the first visit.~No other food or beverage are ingested from 1800 hours the evening before the intervention day until breakfast the day after intervention (no exact time).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alpha-Galactosidase
Description: The study is conducted during a total of two days at two different occasions. Visit 1: The patients will be served breakfast and lunch at the gastro unit and dinner will be enclosed when the patient leave for home. At each meal (breakfast, lunch, and dinner) the participants will ingest three capsules with a total content of 1200 GaIU alpha-galactosidase-randomized to be either the enzyme (α-Galactosidase) or a non-active substance (placebo). Visit 2: The procedure from visit 1 will recur after at least two weeks has passed - except that the content of the capsules will be opposite from the first visit.~No other food or beverage are ingested from 1800 hours the evening before the intervention day until breakfast the day after intervention (no exact time).
Study: NCT01525433

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DVD
Description: Participants will received a mailed DVD containing culturally appropriate information about the importance of cervical cancer screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Promotora
Description: Participants will receive a home visit from a lay community health educator ('Promotora') and will be shown a DVD containing culturally appropriate information to educate participants about the importance of cervical cancer screening
Study: NCT02833155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO